IDXX
IDEXX Laboratories, Inc. NASDAQ Listed Jun 21, 1991$572.32
Mkt Cap $45.5B
52w Low $485.41
30.5% of range
52w High $769.98
50d MA $585.45
200d MA $641.97
P/E (TTM)
43.1x
EV/EBITDA
37.5x
P/B
28.3x
Debt/Equity
0.7x
ROE
66.0%
P/FCF
51.4x
RSI (14)
—
ATR (14)
—
Beta
1.72
50d MA
$585.45
200d MA
$641.97
Avg Volume
533.7K
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
One IDEXX Drive · Westbrook, ME 04092 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | TNS | 3.41 | 3.47 | +1.8% | 562.97 | -0.2% | +2.9% | +1.6% | — | — | — | — |
| Feb 2, 2026 | TNS | 2.93 | 3.08 | +5.1% | 639.60 | -0.6% | -1.1% | -1.1% | +0.5% | +0.6% | +0.8% | — |
| Nov 3, 2025 | TNS | 3.14 | 3.40 | +8.3% | 722.94 | -0.8% | -0.1% | -0.1% | -0.4% | -1.3% | -2.0% | — |
| Aug 4, 2025 | TNS | 3.28 | 3.63 | +10.7% | 682.78 | -0.9% | -6.0% | -6.0% | -8.6% | -4.8% | -3.6% | — |
| May 1, 2025 | TNS | 2.85 | 2.96 | +3.9% | 471.38 | +1.4% | +0.1% | +0.1% | +0.8% | +0.5% | +3.2% | — |
| Feb 3, 2025 | TNS | 2.39 | 2.62 | +9.6% | 469.04 | -1.0% | -0.9% | -0.9% | -0.1% | -1.8% | -2.0% | — |
| Oct 31, 2024 | TNS | 2.68 | 2.80 | +4.5% | 406.92 | +0.4% | +2.5% | +2.5% | +1.9% | +2.2% | +4.1% | — |
| Aug 6, 2024 | TNS | 2.88 | 3.02 | +4.9% | 469.37 | +0.5% | -0.5% | -0.5% | +3.1% | +2.9% | +2.2% | — |
| May 1, 2024 | TNS | 2.67 | 2.81 | +5.2% | 468.04 | -0.5% | +1.7% | +1.7% | +2.7% | +1.9% | +3.3% | — |
| Feb 5, 2024 | TNS | 2.12 | 2.32 | +9.4% | 572.12 | +0.7% | -0.9% | -0.9% | +0.0% | +0.3% | +0.0% | — |
| Nov 1, 2023 | TNS | 2.37 | 2.53 | +6.8% | 395.35 | +1.5% | +6.1% | +6.1% | +8.6% | +7.0% | +6.9% | — |
| Aug 1, 2023 | TNS | 2.47 | 2.67 | +8.1% | 532.30 | -0.8% | -2.5% | -2.5% | -4.6% | -5.3% | -4.5% | — |
| May 2, 2023 | BMO | 2.42 | 2.55 | +5.4% | 467.38 | +0.9% | +2.4% | +2.4% | +0.5% | +4.5% | +3.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | UBS | Maintains | Neutral → Neutral | — | $574.95 | $575.16 | +0.0% | -1.2% | -3.7% | -2.5% | -1.3% | -2.1% |
| Mar 31 | Stifel | Maintains | Buy → Buy | — | $557.09 | $560.04 | +0.5% | +0.9% | +1.4% | +2.2% | +3.7% | +3.2% |
| Feb 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $644.61 | $647.72 | +0.5% | -0.7% | +0.3% | +0.6% | -4.3% | -2.4% |
| Feb 5 | Barclays | Maintains | Overweight → Overweight | — | $642.94 | $643.83 | +0.1% | +0.1% | +0.3% | -0.5% | +0.6% | +0.9% |
| Feb 3 | UBS | Maintains | Neutral → Neutral | — | $639.60 | $635.59 | -0.6% | -1.1% | +0.5% | +0.6% | +0.8% | +0.0% |
| Feb 3 | BTIG | Maintains | Buy → Buy | — | $639.60 | $635.59 | -0.6% | -1.1% | +0.5% | +0.6% | +0.8% | +0.0% |
| Nov 4 | UBS | Maintains | Neutral → Neutral | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.4% | -1.3% | -2.0% | -1.8% |
| Nov 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.4% | -1.3% | -2.0% | -1.8% |
| Nov 4 | BTIG | Maintains | Buy → Buy | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.4% | -1.3% | -2.0% | -1.8% |
| Nov 4 | JP Morgan | Maintains | Overweight → Overweight | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.4% | -1.3% | -2.0% | -1.8% |
| Oct 31 | Stifel | Upgrade | Hold → Buy | — | $628.54 | $634.51 | +0.9% | +0.2% | +15.0% | +14.9% | +14.6% | +13.6% |
| Aug 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $653.95 | $655.54 | +0.2% | -0.5% | -2.5% | -2.6% | -2.2% | -3.2% |
| Aug 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $658.06 | $662.00 | +0.6% | -0.9% | -0.9% | +0.9% | -0.6% | -1.1% |
| Aug 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $535.54 | $662.24 | +23.7% | +27.5% | +19.9% | +16.6% | +21.4% | +22.9% |
| Aug 4 | JP Morgan | Maintains | Overweight → Overweight | — | $535.54 | $662.24 | +23.7% | +27.5% | +19.9% | +16.6% | +21.4% | +22.9% |
| Jul 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $566.50 | $568.90 | +0.4% | +1.2% | +1.0% | -5.7% | -5.5% | +20.5% |
| Jul 17 | Leerink Partners | Maintains | Outperform → Outperform | — | $520.57 | $518.60 | -0.4% | -0.4% | -1.1% | +0.1% | +2.2% | +3.9% |
| Jul 2 | Stifel | Maintains | Hold → Hold | — | $542.65 | $541.48 | -0.2% | +0.0% | +0.8% | +0.5% | -0.7% | -0.4% |
| Jun 11 | Leerink Partners | Maintains | Outperform → Outperform | — | $525.93 | $526.31 | +0.1% | -0.3% | +0.2% | -0.6% | +0.5% | -1.0% |
| May 19 | Stifel | Maintains | Hold → Hold | — | $518.10 | $511.83 | -1.2% | +0.7% | -0.2% | -3.3% | -2.6% | -3.2% |
| May 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $471.90 | $471.90 | +0.0% | +0.7% | +0.4% | +3.1% | +3.8% | +4.2% |
| May 1 | Stifel | Maintains | Hold → Hold | — | $432.65 | $468.18 | +8.2% | +9.0% | +9.1% | +9.8% | +9.5% | +12.5% |
| Apr 21 | BofA Securities | Maintains | Neutral → Neutral | — | $411.49 | $409.47 | -0.5% | -1.2% | +2.5% | +3.7% | +7.2% | +6.3% |
| Apr 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $404.65 | $404.89 | +0.1% | -0.2% | -0.6% | +1.7% | +0.5% | +4.2% |
| Apr 14 | Stifel | Maintains | Hold → Hold | — | $390.94 | $394.00 | +0.8% | +3.5% | +3.3% | +2.9% | +5.3% | +4.0% |
| Feb 28 | Stifel | Maintains | Hold → Hold | — | $441.03 | $442.01 | +0.2% | -0.9% | -0.9% | +0.1% | -0.9% | -2.7% |
| Feb 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $459.78 | $460.68 | +0.2% | +1.1% | +0.9% | -0.5% | -0.0% | -3.3% |
| Feb 4 | Barclays | Maintains | Overweight → Overweight | — | $469.04 | $464.47 | -1.0% | -0.9% | -0.1% | -1.8% | -2.0% | -0.9% |
| Feb 4 | BofA Securities | Maintains | Neutral → Neutral | — | $469.04 | $464.47 | -1.0% | -0.9% | -0.1% | -1.8% | -2.0% | -0.9% |
| Feb 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $469.04 | $464.47 | -1.0% | -0.9% | -0.1% | -1.8% | -2.0% | -0.9% |
| Feb 3 | Stifel | Maintains | Hold → Hold | — | $422.05 | $465.00 | +10.2% | +11.1% | +10.2% | +11.0% | +9.1% | +8.9% |
| Jan 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $417.86 | $417.95 | +0.0% | +0.2% | +1.5% | +1.0% | +12.2% | +11.3% |
| Nov 4 | Barclays | Maintains | Overweight → Overweight | — | $417.28 | $419.36 | +0.5% | -0.7% | -0.3% | +1.5% | +3.8% | +3.8% |
| Nov 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $417.28 | $419.36 | +0.5% | -0.7% | -0.3% | +1.5% | +3.8% | +3.8% |
| Oct 11 | JP Morgan | Maintains | Overweight → Overweight | — | $473.28 | $474.92 | +0.3% | +0.6% | +1.0% | +0.1% | -2.0% | -2.8% |
| Oct 10 | Stifel | Maintains | Hold → Hold | — | $474.65 | $468.00 | -1.4% | -0.3% | +0.3% | +0.7% | -0.2% | -2.3% |
| Aug 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $487.82 | $485.51 | -0.5% | -2.6% | -0.5% | +0.9% | +1.9% | +1.3% |
| Jun 24 | Stifel | Maintains | Hold → Hold | — | $495.73 | $494.40 | -0.3% | -0.9% | -0.9% | -1.4% | -0.4% | -1.7% |
| May 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $503.02 | $505.76 | +0.5% | +3.6% | +9.0% | +7.5% | +8.0% | +5.4% |
| May 2 | Barclays | Maintains | Overweight → Overweight | — | $468.04 | $465.60 | -0.5% | +1.7% | +2.7% | +1.9% | +3.3% | +4.1% |
| Feb 6 | Barclays | Maintains | Overweight → Overweight | — | $572.12 | $575.96 | +0.7% | -0.9% | +0.0% | +0.3% | +0.0% | -1.1% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $572.12 | $575.96 | +0.7% | -0.9% | +0.0% | +0.3% | +0.0% | -1.1% |
| Jan 30 | Piper Sandler | Downgrade | Overweight → Neutral | — | $532.06 | $520.80 | -2.1% | -2.1% | -3.2% | -0.9% | -0.9% | +7.5% |
| Jan 17 | Goldman Sachs | Maintains | Buy → Buy | — | $520.00 | $516.23 | -0.7% | -0.9% | +1.0% | +0.7% | +2.2% | +2.2% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $429.30 | $430.92 | +0.4% | -1.5% | -1.6% | -0.4% | -2.5% | -0.1% |
| Nov 3 | Goldman Sachs | Maintains | Buy → Buy | — | $419.44 | $425.04 | +1.3% | +2.4% | +0.9% | +0.7% | +2.0% | -0.2% |
| Nov 2 | JP Morgan | Maintains | Overweight → Overweight | — | $395.35 | $401.17 | +1.5% | +6.1% | +8.6% | +7.0% | +6.9% | +8.2% |
| Nov 2 | Barclays | Maintains | Overweight → Overweight | — | $395.35 | $401.17 | +1.5% | +6.1% | +8.6% | +7.0% | +6.9% | +8.2% |
| Oct 30 | Stifel | Maintains | Hold → Hold | — | $391.37 | $394.10 | +0.7% | +1.3% | +2.1% | +1.0% | +7.2% | +9.7% |
| Sep 15 | Stifel | Maintains | Hold → Hold | — | $462.08 | $456.46 | -1.2% | -2.5% | -2.6% | -1.0% | -1.5% | -5.1% |
No insider trades available.
8-K · 2.02
!! High
IDEXX Laboratories, Inc. -- 8-K 2.02: Earnings Results
IDEXX Laboratories reported quarterly earnings results, with full details available in the accompanying press release, providing investors insight into the company's operational performance and financial health.
May 5
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
IDXX's departure of a key executive, with accelerated vesting of equity awards, signals leadership transition costs and potential talent loss that could impact operational execution and shareholder value.
Mar 26
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott Laboratories' appointment of a new executive effective April 1, 2026, signals potential strategic shifts in operations or leadership direction that could affect near-term stock performance and investor confidence in company management.
Mar 18
8-K
DENTSPLY SIRONA Inc. -- 8-K Filing
DENTSPLY SIRONA strengthened its board with three experienced executives from dental and financial sectors, including Morgan Stanley's former investment banking leader and IDEXX's ex-CFO, signaling potential strategic shifts ahead.
Feb 26
8-K · 5.02
!!! Very High
DENTSPLY SIRONA Inc. -- 8-K 5.02: Executive Change
DENTSPLY SIRONA appointed James D. Forbes as director while Willie A. Deese resigned, signaling potential strategic shifts in board composition and governance priorities.
Feb 24
8-K · 5.02
!!! Very High
Idexx Laboratories Inc -- 8-K 5.02: Executive Change
IDEXX Laboratories announces board member Anne Szostak's retirement, with no reported disagreements concerning company operations or policies.
Feb 13
8-K · 5.02
!!! Very High
Piper Sandler Companies -- 8-K 5.02: Executive Change
Piper Sandler Companies appointed Stuart M. Essig as a director, expanding its board leadership potentially with his industry expertise.
Feb 4
8-K
Idexx Laboratories Inc -- 8-K Filing
IDEXX Laboratories reported fourth quarter 2025 revenue growth of 14% as reported and 12% organically, driven by strong performance in its CAG Diagnostics recurring revenue segment.
Feb 2
Data updated apr 25, 2026 2:59pm
· Source: massive.com